Case Report

Promyelocytic Sarcoma of the Spine: A Case Report and Review of the Literature

Leonardo Pacilli,1 Francesco Lo Coco,2 Safaa Mahmoud Ramadan,2 Laura Gianni,2 Alberto Pingi,1 Daniele Remotti,1 and Ignazio Majolino1

1Hematology and BMT Unit, Institute of Hematotherapy, Ospedale S. Camillo, 00153 Rome, Italy
2Department of Biopathology, Tor Vergata University, 00133 Rome, Italy

Correspondence should be addressed to Leonardo Pacilli, lpacilli@scamilloforlanini.rm.it

Received 5 August 2009; Accepted 15 January 2010

Academic Editor: Stefan Faderl

Copyright © 2010 Leonardo Pacilli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon in acute promyelocytic leukemia (APL). In the case described here, MS was the sole site of APL relapse and the cause of spinal cord compression. The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission. He was treated with excision of the mass followed by local radiotherapy. Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.

1. Introduction

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells [1]. It can occur in association with myelogenous leukemia, myeloproliferative disorders, and myelodysplasia. MS has different modalities of presentation and can affect any organ. It may occur otherwise in healthy individuals who subsequently develop an overt typical myelogenous leukemia [1, 2]. MS can also develop in leukemia patients concurrently with or after diagnosis, or as a manifestation of disease relapse [3, 4]. The WHO recognizes three major variants of MS based on the predominant cell type and the degree of maturation, namely respectively, a myeloblast variant, with a mix of myeloblasts and promyelocytes variant, and more differentiated variant with promyelocytes and more mature granulocytes [5]. Acute promyelocytic leukemia (APL) accounts for approximately 10% of acute myeloid leukemia (AML) and cases of MS due to APL have been only occasionally reported [1–4]. We report the case of a patient with APL who presented right paraparesis after 7 years of complete remission. The patient had a MS with paravertebral localization as the only site of APL relapse.

2. Case Report

In November 1999, a 38-year-old male presented with a history of recurrent episodes of gum bleeding. Physical examination was unremarkable, but a complete blood count showed Hb 6.1 g/dL, WBC $1 \times 10^9/L$, and platelets $2 \times 10^9/L$. Microscopic examination of a blood smear showed 8% hypergranular promyelocytes, with Auer rods. At examination of bone marrow aspirate a diffuse infiltration by atypical promyelocytes was apparent. The immunophenotype profile of leukemic cells was consistent with APL (CD33+ve, CD45+ve, HLA-DR-ve, CD34-ve, CD16-ve, and CD56-ve). Cytogenetics revealed the characteristic t(15;17) (q22;q21-q22) and the RT-PCR assay showed the typical PML/RARα fusion gene thereby confirming the diagnosis of APL [6]. The patient was treated with all-trans retinoic
acid (ATRA) 45 mg/m²/day for 30 days and idarubicin (IDA) 12 mg/m²/day on days 2, 4, 6, and 8. On day 20, the patient had severe pulmonary distress that was consistent with an ATRA syndrome [7]. This was successfully managed with high-dose dexamethasone and ATRA discontinuation. Despite that, following induction, bone marrow evaluation revealed a morphologic and molecular picture of complete remission. The patient received 3 additional courses of chemotherapy as consolidation and completed his treatment in July 2002. Five years later in July 2007, the patient presented with right chest pain and progressive right paraparesis in a few-week duration. An MRI of the spine revealed a solid extramedullary intraspinal mass extending between T6 and T8. Diagnostic workup including coagulation profile and complete blood counts was normal, and neither atypical promyelocytes nor blast cells were detected in peripheral blood and bone marrow. In addition, PCR analysis for PML/RARα transcribed on bone marrow cells confirmed a status of molecular remission. Cord decompression was performed with total laminectomy and excision of an extradural soft tissue mass of 4 cm × 5 cm × 5 cm. Histopathology examination showed diffuse infiltration by monomorphic, medium-sized, neoplastic cells with round shaped deeply indented or bilobated nuclei with dispersed chromatin, inconspicuous nucleoli, and basophilic cytoplasm. The immunophenotype characteristics of neoplastic cells were as follows: myeloperoxidase and CD117 (c-KIT) were strongly positive; CD45 was weakly and focally expressed while CD34, CD31, CD20, CD79a, CD3, CD56, and CD15 were negative. Cytogenetic studies showed (Figure 1) t(15;17) (q22;q21-q22) with PML/RARα fusion gene as demonstrated by FISH LSI with PML/RARα probe dual color (Dual fusion translocation probe, Vysis/Abbot). Since the disease was localized to the spine, the patient underwent a local radiotherapy with 36 Gy.

3. Discussion

Extramedullary disease (EMD) at diagnosis or at relapse develops in 3%–8% of patients with acute myelogenous leukemia, more frequently in those with myelomonocytic and monocytic morphology [9–11] (M4 and M5 French-American-British subtypes). Its occurrence in APL is relatively rare but after the advent of ATRA it is increasingly reported at time of relapse [11–29]. The case reported here, is a rare case of CNS isolated relapse [13]. The patient presented with neurologic symptoms due to a paravertebral mass after 7 years of complete remission. He entered a second prolonged clinical and molecular remission after local radiotherapy followed by a combination of ATRA and ATO. This case represents the second report of MS resulting in spinal cord compression due to APL extramedullary relapse. The other case, reported by Tsimberidou et al. [30], was a man who remained in complete remission for 3 years after treatment of APL. This patient later developed paraplegia due to a paravertebral mass at the level of T7-T8. Following decompression laminectomy, an isolated extramedullary promyelocytic relapse was diagnosed. The bone marrow was not involved. The patient was treated with local radiotherapy followed by ATRA and idarubicin, achieving a short second remission. He subsequently developed a second relapse with marrow and skin involvement.

The occurrence of EMD has long been considered a rare event in APL patients treated with chemotherapy alone, whereas this phenomenon has increasingly been reported in the ATRA era [5, 9, 38]. The question arises as to whether treatment of APL with ATRA predisposes patients to the development of EMD [38, 51]. This question is still open, as various trials have shown contrasting results. Wiernik et al. [3] suggested that extramedullary APL occurs more frequently after ATRA than other therapies. Ko et al. [23] demonstrated that patients receiving ATRA induction had a 2.1 increased relative risk of EMD compared with those with chemotherapy alone. In a literature review by Bae et al. [51], only three of 21 cases with CNS relapse received systemic chemotherapy without ATRA. Among 172 patients with APL treated at MDACC between 1980 and 2003, a total of three patients relapsed with isolated EMD and it occurred exclusively in patients who had received ATRA-containing induction regimens [51]. Ohno et al. [52] noted that EM relapse was absent from all 37 patients with relapsing APL in the Japanese chemotherapy only studies, while it was seen in 8% of 121 patients in the chemotherapy plus ATRA protocols and this raised the possibility that the doses of chemotherapy given with ATRA-based regimens are less intensive than those previously used and thus may not reach therapeutic levels in the EM tissues. This could be particularly relevant to protocols without cytarabine. A relationship between EMD and ATRA treatment has been suggested. Two possible explanations are considered. The first suggests a direct effect of ATRA on adhesion molecules resulting in increased infiltration capability of APL leukemia blasts [23]. The second postulates the occurrence of MS in relapsed patients as a consequence of the prolonged survival [38]. In a study of the GIMEMA [38], the authors found
### Table 1: Clinical features of patients with MS in APL.

| References                 | No. cases | disease status | Time since diagnosis/EMD relapse (months) | Site of involvement                                                                 |
|----------------------------|-----------|----------------|-------------------------------------------|-----------------------------------------------------------------------------------|
| Fukushima et al. [31]      | 1         | onset          |                                           | cerebellum + hematological                                                       |
| Worch et al. [32]          | 1         | onset          |                                           | lytic lesions of humerus, tibia, femur + molecular hematological                  |
| Ajarim et al. [33]         | 1         | onset          |                                           | thymus + hematological                                                            |
| Savranlar et al. [34]      | 1         | onset          |                                           | thoracic-epidural                                                                |
| Brown et al. [35]          | 1         | onset          |                                           | optic nerve + hematological                                                       |
| Agarwal et al. [36]        | 1         | relapse        | 31                                        | hip + hematological                                                               |
| Disel et al. [37]          | 1         | relapse        | 9                                         | pleura                                                                          |
| Tsimerodou et al. [30]     | 1         | relapse        | 36                                        | thoracic spine                                                                   |
| Specchia et al. [38]       | 1         | relapse        | NA                                        | lung + hematological                                                              |
| Tsimberodou et al. [30]    | 3         | relapse        | 155                                       | mastoid + hematological                                                           |
| Latagliata et al. [39]     | 7         | onset          | 61                                        | mastoid                                                                          |
|                            |           |                | 3 relapse 7                               | subcutaneous nodules at sternal manubrium + wrist at level of the radial artery pulse + site of intravenous catheter scar+ mol hematological |
| Sanz et al. [40]           |           |                | 6                                         | sternal manubrium + subcutaneous nodule + antecubital fossa                       |
| Magliulo et al. [41]       | 1         | relapse        | 24                                        | external auditory canal+ mol hematological                                        |
| Nasilowska-Adamska et al. [42] | 1         | relapse        | 21                                        | pleura, heart and pericardium                                                    |
| Slavecheva et al. [43]     | 1         | relapse        | 120                                       | lymph node                                                                       |
| Kai et al. [44]            | 1         | relapses       | NA                                        | 4 time at different sites                                                         |
| Tobita et al. [45]         | 1         | relapses       | NA                                        | 1st and 2nd external auditory canal                                              |
| Forrest et al. [46]        | 1         | relapse        | 1st 48-2nd 24                             | 1st testicular -2nd retroperitoneal nodes, psoas muscle and skin                  |
| Skarin et al. [47]         | 1         | relapse        | 8                                         | CNS + hematologic                                                                 |
|                            |           |                |                                           | (1) central nervous system + middle ear + lymph nodes.                           |
|                            |           |                |                                           | (2) skin + lymph nodes                                                            |
|                            |           |                |                                           | 1st and 2nd -scalp + mol hematological 3rd mol hematological + breast            |
|                            |           |                |                                           | (1) left auricular canal + mastoid + mol hematological                           |
|                            |           |                |                                           | (2) left mastoid + mol hematological                                              |
|                            |           |                |                                           | (3) left mastoid                                                                 |
|                            |           |                |                                           | (4) left mastoid + hematologic                                                    |
|                            |           |                |                                           | (5) left mastoid + hematologic                                                    |
|                            |           |                |                                           | (6) right auricular canal                                                         |
|                            |           |                |                                           | (7) right mastoid + CNS + mol hematological                                      |
| Ammatuna et al. [49]       | 1         | relapse        | 5 from CR                                |                                                                                  |
| Breccia et al. [50]        | 7         | relapse        | 6 from 2nd CR                            |                                                                                  |

NA: not available; mol: molecular; CR: complete remission;
no statistical difference in the frequency of extramedullary involvement between patients treated with or without ATRA. EMD was documented in 5% and 12% of patients included in the LAP0389 and AIDA protocol, respectively, with no statistical difference. In particular, the five EMD localizations in the LAP0389 study were in the CNS (1 patient), the skin (3 patients), and the middle ear (1 patient). Of the 16 EMD relapses in the AIDA study, 10 involved the CNS and six involved other extramedullary sites (the skin in 3, the middle ear in 2, and the lung in 1). Thus CNS disease at relapse seems frequent among the AIDA treated patients (8% versus 1%) [39]. Breccia et al. [50] described three adult patients with middle ear localizations at relapse. They had been previously treated with ATRA and CT. Their characteristics are shown in Table 1.

Similarly, C. Samanze et al. [53] reported 7 cases of EMD relapse in APL patients receiving chemotherapy (CT) alone (102 patients) or combined with ATRA (155 patients). EMD relapse rate was 4.4% in the CT group and 8.7% in the group CT plus ATRA, with no statistical differences. EMD localizations were in soft tissues (3 patients), the CNS (2 patients), the tonsils (1 patient), liver (1 patient), and the testis (1 patient). De Botton et al. [54] analyzed EMD relapse occurring in patients with APL treated with ATRA and CT. Of 740 patients included in three multicenter trials (APL91, APL93 trials, and PETHEMA 96) 10 patients developed EMD relapse. Of these, 9 were in the CNS and one in the skin. Only two patients had isolated EMD relapses. A significant correlation could be found between high WBC count and the risk of CNS relapse. More recently, Casanova et al. [55] reported a similar pattern of increased CNS EMD relapse in APL patients treated with ATRA and CT. EMD relapse was found in 8 of 74 (15%) APL patients (CNS: 5, external ear: 3). Together, these studies confirm that the CNS is the preferential site of extramedullary involvement in APL, raising an issue of whether or not to consider CNS prophylaxis in APL treatment protocols especially in patients presenting with hyperleukocytosis, as suggested by the expert panel of the European Leukemia Net. However, the benefit of this policy has not been established in prospective studies [56]. The occurrence of the ATRA syndrome was recognized to be a significant risk factor for EMD involvement at relapse [57]. Since APL cells, in patients affected by ATRA syndrome, infiltrate multiple tissues and organs, including the lung and the skin, it was hypothesized that ATRA could promote the migration of differentiating blasts into the skin, the CNS, and other tissues which represented a reservoir of viable blasts. These cells could later proliferate and result in an EMD recurrence [9, 11, 23, 27, 57]. Others have found that elevated WBC count (>10 × 10^9 L) on presentation [55], predominance of the PML/RARα bcr3 type, and mirogranular morphology [50] are considered as risk factors.

Management of relapse in the CNS and other extramedullary sites in patients with APL is a challenging issue for which there is a notable lack of information. EMD relapse, including in the CNS, can occur either in isolation or associated with BM involvement as a first relapse, and also after one or more hematologic relapses. Optimal management and outcome of APL patients in these different situations have not been critically assessed. In case of granulocytic sarcoma, wherever it is localized, radiation and intensive systemic therapy might be considered.

Before the demonstration of the striking activity of ATO in APL, salvage therapy usually consisted of the readmin-istration of ATRA and chemotherapy for induction, generally containing high-dose cytarabine and an anthracycline, followed by further chemotherapy and/or hematopoietic stem cell transplantation (HSCT) [58–60]. Confirmation of the high and sustained efficacy of ATO in patients with relapsed/refractory APL has been provided by more recent studies [61, 62]. CR rates in these trials were 80%–90% and, in those studies that evaluated survival, 50%–70% of patients were alive at 1 for 3 years. Current evidence suggests that the use of at least 2 cycles of ATO results in the achievement of second molecular CR in nearly 80% of cases [63]. The best consolidation strategy after ATO induced second remission is unknown; options include continued treatment with repeated cycles of ATO, the use of standard chemotherapy in combination with ATRA and/or ATO, and HSCT. For patients unfit to proceed to HSCT, the available options include repeated cycles of ATO with or without ATRA/standard chemotherapy.

The central nervous system (CNS) is the commonest site of extramedullary disease in APL and at least 10% of hematologic relapses are accompanied by CNS involvement [11]. Because the majority of CNS relapses occur in patients presenting with hyperleukocytosis some strategies include CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.

CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.

In conclusion, the increasing number and special pattern of EMD involvement in relapsing APL patients emphasize its importance in the differential diagnosis of EMD localization in patients with history of APL. They also highlight the need for understanding the underlying pathogenesis and predisposing factors, as well as for selecting the optimal treatment approach.

References

[1] R. S. Neiman, M. Barcos, C. Berard, et al., “Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases,” Cancer, vol. 46, no. 6, pp. 1426–1437, 1981.
[2] L. P. Menasce, S. S. Banerjee, E. Beckett, and M. Harris, “Extra-medullary myeloid tumour (granulocytic sarcoma) is often
misdiagnosed: a study of 26 cases,” Histopathology, vol. 34, no. 5, pp. 391–398, 1999.

[3] P. H. Wiernik, R. De Bellis, P. Muxi, and J. P. Dutcher, “Extramedullary acute promyelocytic leukemia,” Cancer, vol. 78, p. 25, 1996.

[4] M. Benekli, M. C. Savas, I. C. Haznedaroglu, and S. V. Dündar, “Granulocytic sarcoma in acute promyelocytic leukemia,” Leukemia and Lymphoma, vol. 22, no. 1–2, pp. 183–185, 1996.

[5] E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, Eds., World Health Organisation Classification of Tumours—Tumours of Haematopoietic and Lymphoid Tissues, vol. 105, IARC Press, London, UK, 2001.

[6] P. Fenaux, C. Chomienne, and L. Degos, “Acute promyelocytic leukemia: biology and treatment,” Seminars in Oncology, vol. 24, no. 1, pp. 92–102, 1997.

[7] R. S. Larson and M. S. Tallman, “Retinoic acid syndrome: manifestations, pathogenesis, and treatment,” Best Practice and Research: Clinical Haematology, vol. 16, no. 3, pp. 453–461, 2003.

[8] E. Estey, G. Garcia-Manero, A. Ferrajoli, et al., “Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,” Blood, vol. 107, no. 9, pp. 3469–3473, 2006.

[9] V. Liso, G. Specchia, E. M. Pogliani, et al., “Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases,” Cancer, vol. 83, no. 8, pp. 1522–1528, 1998.

[10] A.-M. Tsimberidou, H. M. Kantarjian, E. Estey, et al., “Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy,” Leukemia, vol. 17, no. 6, pp. 1100–1103, 2003.

[11] G. D. Evans and D. J. Grimwade, “Extramedullary disease is acute promyelocytic leukemia,” Leukemia and Lymphoma, vol. 33, no. 3–4, pp. 219–229, 1999.

[12] L. Degos, “All-trans retinoic acid (ATRA) therapeutic effect in acute promyelocytic leukemia,” Biomedicine and Pharmacotherapy, vol. 46, no. 5–7, pp. 201–209, 1992.

[13] Y. Kanakura, T. Yonezawa, Y. Hamaguchi, et al., “Acute promyelocytic leukemia with an intracerebral mass and meningeal involvement after treatment of non-Hodgkin’s lymphoma,” Cancer, vol. 59, no. 1, pp. 94–98, 1987.

[14] R. Marra, S. Stori, L. Pagano, et al., “Central nervous system acute promyelocytic leukemia: a report of three cases,” Haematologica, vol. 22, no. 3, pp. 195–199, 1989.

[15] Z. Niazi, P. Molt, A. Mittelman, Z. A. Arlin, and T. Ahmed, “Leukemic dermal infiltrates at permanent indwelling central venous catheter insertion sites,” Cancer, vol. 68, no. 10, pp. 2281–2283, 1991.

[16] M. R. Baer, M. Barcos, H. Farrell, A. Raza, and H. D. Preisler, “Acute myelogenous leukemia with leukemia cutis. eighteen cases seen between 1969 and 1986,” Cancer, vol. 63, no. 11, pp. 2192–2200, 1989.

[17] T. A. Longacre and B. R. Smoller, “Leukemia cutis: analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes,” American Journal of Clinical Pathology, vol. 100, no. 3, pp. 276–284, 1993.

[18] S. Giralt, S. O’Brien, E. Weeks, M. Luna, and H. Kantarjian, “Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid,” Leukemia and Lymphoma, vol. 14, no. 5–6, pp. 453–456, 1994.

[19] G. Evans, D. Grimwade, H. G. Prentice, and N. Simpson, “Central nervous system relapse in acute promyelocytic leukemia in patients treated with all-trans retinoic acid,” British Journal of Haematology, vol. 98, no. 2, pp. 437–439, 1997.

[20] A. Menendez, A. Gonzalez, H. Cabrera, et al., “Clinical spectrum of extramedullary acute promyelocytic leukemia,” European Journal of Haematology, vol. 64, no. 3, pp. 201–203, 2000.

[21] J. C. Byrd and R. B. Weiss, “Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule,” Cancer, vol. 73, no. 8, pp. 2107–2112, 1994.

[22] L. D. Burry and J. T. Seki, “CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid;” Annals of Pharmacotherapy, vol. 36, no. 12, pp. 1900–1906, 2002.

[23] B.-S. Ko, J.-L. Tang, Y.-C. Chen, et al., “Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia—the occurrence of retinoic acid syndrome is a risk factor,” Leukemia, vol. 13, no. 9, pp. 1406–1408, 1999.

[24] K. Yamauchi and M. Yasuda, “Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature,” Cancer, vol. 94, no. 6, pp. 1739–1746, 2002.

[25] J. R. Post, E. Espinosa, R. Losada, C. Hernandez, G. Martinez, and P. Hernandez, “Parotid and central nervous system relapse during complete hematologic remission in acute promyelocytic leukemia,” Haematologica, vol. 84, no. 6, pp. 565–566, 1999.

[26] M. Seldon and A. Enno, “Central nervous system relapse in acute promyelocytic leukaemia treated with all-trans retinoic acid,” Australian and New Zealand Journal of Medicine, vol. 28, no. 4, p. 462, 1998.

[27] M. A. Weiss and R. P. Warrell Jr., “Two cases of extramedullary acute promyelocytic leukemia: cytogenetics, molecular biology, and phenotypic and clinical studies,” Cancer, vol. 74, no. 7, pp. 1882–1886, 1994.

[28] G. Milone, G. Inghilterra, E. Li Gioi, et al., “Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL,” Bone Marrow Transplantation, vol. 23, no. 7, pp. 751, 1999.

[29] T. Kai, H. Kimura, Y. Shiga, K. Ogawa, H. Sato, and Y. Maruyama, “Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy,” International Journal of Hematology, vol. 83, no. 4, pp. 337–340, 2006.

[30] A. M. Tsimberidou, E. Estey, G. J. Whitman, et al., “Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide—all-trans retinoic acid and gentuzumab ozogamicin therapies,” Leukemia Research, vol. 28, pp. 991–994, 2004.

[31] S. Fukushima, M. Terasaki, Y. Tajima, and M. Shigemori, “Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report,” Journal of Neurosurgery, vol. 105, no. 6, pp. 912–915, 2006.

[32] J. Woroch, J. Ritter, and M. C. Frühwald, “Presentation of acute promyelocytic leukemia as granulocytic sarcoma,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 657–660, 2008.
A. Savranlar, Y. Ustündag, T. Ozer, et al., “A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment,” Acta Medica Okayama, vol. 58, no. 5, pp. 251–254, 2004.

D. M. Brown, A. E. Kimura, K. C. Ossoinig, and G. J. Weiner, "Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid," Ophthalmology, vol. 99, no. 9, pp. 1463–1467, 1992.

N. Agarwal, E. M. Tepe, A. Mishra, and J. H. Ward, "Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip," Annals of Hematology, vol. 85, no. 10, pp. 741–742, 2006.

U. Disel, S. Yavuz, S. Paydas, B. Sahin, and H. Zeren, "Extradural relapse in the pleura in acute promyelocytic leukemia," Leukemia and Lymphoma, vol. 44, no. 1, pp. 189–191, 2003.

G. Specchia, F. Lo Coco, M. Vignetti, et al., "Extradurillary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell’Adulto," Journal of Clinical Oncology, vol. 19, no. 20, pp. 4023–4028, 2001.

R. Latagliata, I. Carmosino, M. Breccia, et al., “Late relapses in acute promyelocytic leukaemia,” Acta Haematologica, vol. 117, no. 2, pp. 106–108, 2007.

M. A. Sanz, L. Larrea, G. F. Sanz, et al., “Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukemia,” Haematologica, vol. 85, pp. 758–762, 2000.

G. Magliulo, M. Fusconi, and G. Pulice, “Acute promyelocytic leukaemia and aural recurrence: the importance of otoscopy in early diagnosis,” Leukemia, vol. 17, no. 7, pp. 1418–1419, 2003.

B. Nasilowska-Adamska, M. Majewski, I. Seferynska, et al., “Predictive value of RT-PCR PML-RARA transcript monitoring for extradural relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT,” Annals of Transplantation, vol. 12, no. 3, pp. 33–38, 2007.

V. Slavcheva, T. Lukanov, and N. Tzvetkov, “Two cases of extradural myeloid tumor in patients with continuous remission of acute myeloblastic leukemia,” Journal of BUON, vol. 13, no. 4, pp. 589–592, 2008.

T. K. Hai, K. Kimura, Y. Shiga, K. Ogawa, H. Sato, and Y. Maruyama, “Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy,” International Journal of Hematology, vol. 83, no. 4, pp. 337–340, 2006.

D. L. Forrest, B. I. Dalal, S. C. Naiman, et al., “Testicular relapse of acute promyelocytic leukemia after allogeneic BMT,” Bone Marrow Transplantation, vol. 20, no. 8, pp. 689–690, 1997.

A. Skarin, S. K. Ma, C. Ooi, et al., “CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission,” Journal of Clinical Oncology, vol. 18, pp. 3435–3437, 2000.

F. Leoni, G. Gianfaldoni, M. Annunziata, et al., “Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation,” Haematologica, vol. 87, no. 5, pp. 485–489, 2002.

E. Ammatuna, P. A. Borza, A. P. Iori, et al., “Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukemia,” Leukemia, vol. 19, no. 3, pp. 479–480, 2005.

M. Breccia, M. C. Petti, A. M. Testi, et al., “Ear involvement in acute promyelocytic leukemia at relapse: a disease associated ‘sacrament’?” Leukemia, vol. 16, no. 6, pp. 1127–1130, 2002.

S. H. Bae, H. M. Ryoo, H. S. Cho, J. L. Lee, K. H. Lee, and M. S. Hyun, “Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature,” Journal of Korean Medical Science, vol. 19, no. 2, pp. 311–314, 2004.

R. Ohno, N. Asou, and K. Ohnishi, “Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate,” Leukemia, vol. 11, no. 8, pp. 1454–1463, 2003.

C. Samanez, S. Santillana, J. Leon, A. Wachtel, C. Vallejos, and Instituto de Enfermedades Neoplasicas, Lima, Peru, “Pattern of extramedullary relapse in acute promyelocytic leukemia (APL) in Peruvian patients,” in Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO ‘02), vol. 21, 2002, abstract no. 1090.

S. de Botton, M. A. Sanz, S. Chevetet, et al., “Extraduillary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy,” Leukemia, vol. 20, no. 1, pp. 35–41, 2006.

L. A. Casanova, S. M. Quintana, S. P. Neciosup, and C. A. Samanez, “Pattern of extramedullary relapse in latin patients with acute promyelocytic leukaemia (APL) treated with all-trans retinoic acid (ATRA) and chemotherapy,” in Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO ’07), vol. 25, p. 18S, 2007, abstract no. 1752.

M. A. Sanz, D. Grimwade, M. S. Tallman, et al., “Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet,” Blood, vol. 113, no. 9, pp. 1875–1891, 2009.

F. Patriarca, C. Fili, A. Geromin, A. Sperotto, S. Prosdocimo, and R. Fanin, “Activity of all-trans-retinoic acid in a case of central nervous system extradural relapse of acute promyelocytic leukemia,” European Journal of Haematology, vol. 68, no. 5, pp. 310–313, 2002.

J. Esteve, L. Escoda, G. Martin, et al., “Outcome of patients with acute promyelocytic leukaemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention,” Leukemia, vol. 21, no. 3, pp. 446–452, 2007.

E. H. Estey, “Treatment options for relapsed acute promyelocytic leukemia,” Best Practice and Research: Clinical Haematology, vol. 16, no. 3, pp. 521–534, 2003.

X. Thomas, H. Dombret, C. Cordonnier, et al., “Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation,” Leukemia, vol. 14, no. 6, pp. 1006–1013, 2000.

W. Y. Au, A. K. W. Lie, C. S. Chim, et al., “Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia,” Annals of Oncology, vol. 14, no. 5, pp. 752–757, 2003.
[62] K. Shigeno, K. Naito, N. Sahara, et al., “Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies,” International Journal of Hematology, vol. 82, no. 3, pp. 224–229, 2005.

[63] M. S. Tallman, “Treatment of relapsed or refractory acute promyelocytic leukemia,” Best Practice and Research in Clinical Haematology, vol. 20, no. 1, pp. 57–65, 2007.